Table 1 Demographic and clinical features a
Controls (n = 7) | RA (n = 11) | PsA (n = 15) | OA (n = 14) | |
|---|---|---|---|---|
Age, yr | 47 (40 to 60) | 49 (45 to 62) | 48 (34 to 56) | 68 (54 to 77) |
Females, n (%) | 2 (29) | 7 (64) | 7 (47) | 10 (71) |
Disease duration, mo | NA | 18 (8 to 88) | 41 (23 to 84)b | 42 (13 to 72)c |
Erosive disease, n (%) | NA | 3/8 (38) | ND | ND |
RF-positive, n/total (%) | NA | 3/11 (27) | ND | ND |
ACPA-positive, n (%) | NA | 4/7 (57) | ND | ND |
VAS GDA | NA | 57 (55 to 85) | 67 (54 to 75) | ND |
TJC28, n | NA | 9 (7 to 13) | 2 (1 to 12) | ND |
SJC28 | NA | 11 (6 to 14) | 2 (1 to 12) | ND |
ESR, mm/h | NA | 23 (16 to 47) | 34 (8 to 56) | ND |
CRP, mg/L | NA | 24.3 (12.0 to 37.0) | 11.0 (4.7 to 18.0) | ND |
DAS28 | NA | 5.46 (5.33 to 6.62) | 4.67 (2.83 to 5.99) | ND |
NSAID use, n (%) | NA | 7 (64) | 6 (40) | 6 (67)d |
MTX use, n (%) | NA | 6 (55) | 10 (67) | 0 (0) |